Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.32 |
| ▸ | CHRNG | P07510 | 3/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.32 |
| ▸ | CHRND | Q07001 | 3/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170941 | 1.00 | — | — | |
| SCHEMBL6624504 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL27734259 | 0.97 | SMN1; SMN2 (0.44) | SMN1; SMN2FDPSALDH1A1LMNAMEN1 | |
| Bromide SCHEMBL23499956 | 0.97 | SMN1; SMN2 (0.39) | SMN1; SMN2FDPSALDH1A1LMNAMEN1 | |
| Ammonia Solution, Strong SCHEMBL16146085 | 0.97 | SMN1; SMN2 (0.39) | SMN1; SMN2FDPSALDH1A1LMNAMEN1 | |
| SCHEMBL21150247 | 0.97 | — | — | |
| SCHEMBL77786 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL989800 | 0.94 | — | — | |
| SCHEMBL5746901 | 0.90 | — | — | |
| Acetonitrile SCHEMBL4288175 | 0.87 | ALDH1A1 (0.36) | SMN1; SMN2FDPSALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105038159-B | Lactic acid composite material containing reactive macromole type nucleator and preparation method thereof | 常州大学 | 2017-04-05 | — | — | CN | claimed |
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | SMN1; SMN2 3818/4885FDPS 1212/4885ALDH1A1 2165/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | SMN1; SMN2 4162/4885FDPS 2093/4885ALDH1A1 1261/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | SMN1; SMN2 4351/4885FDPS 2033/4885ALDH1A1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.